Can Strata Critical Medical, Inc. (SRTA) Run Higher on Rising Earnings Estimates?
Strata Critical Medical, Inc. (SRTA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
SRTA - Strata Critical Medical, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$7.25
DETAILS
HIGH:
$7.25
LOW:
$7.25
MEDIAN:
$7.25
CONSENSUS:
$7.25
UPSIDE:
22.05%
Stock News
Wall Street Analysts Predict a 60% Upside in Strata Critical Medical, Inc. (SRTA): Here's What You Should Know
The consensus price target hints at a 60% upside potential for Strata Critical Medical, Inc. (SRTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Strata Critical Medical, Inc. (SRTA) Q2 2026 Earnings Call Transcript
Strata Critical Medical, Inc. (SRTA) Q2 2026 Earnings Call Transcript
Strata Critical Medical Announces Second Quarter 2026 Results
Revenue increased 60.7% year-over-year to $72.5 million in Q2 2026 Clinical revenue increased 22.6% sequentially in Q2 2026; Excluding Clinical acquisitions that closed in Q2 2026, Clinical revenue increased 15.1% sequentially driven by a 23.8% increase in Transplant Clinical revenue Q2 2026 net loss from continuing operations of $(10.5) million or (14.5)% of revenue Adjusted EBITDA (1) of $7.9 million in Q2 2026; Adjusted EBITDA margin of 10.9% Cash flow from operating activities was $5.7 million in Q2 2026; Free Cash Flow (1) was $2.9 million in Q2 2026 Completed bolt-on acquisitions of Louisville Perfusion Services, Heart and Lung Transplant National Recovery Program and Ohio Valley Perfusion Associates during Q2 2026 Signed agreement to take over Statline's Transplant Center Organ Placement customer relationships on a rolling basis over the next year NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced financial results for the second quarter ended June 30, 2026. Financial results in this release, including all comparisons to prior year periods, reflect continuing operations only.
Strata Critical Medical Schedules Second Quarter 2026 Earnings Conference Call
NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical. (Nasdaq: SRTA, “Strata” or the “Company”), will release financial results for the second quarter ended July 31, 2026 on Tuesday, August 4, 2026 before the market opens. The company will hold a conference call on the same day at 8:00 am Eastern Time to discuss the results. The call will be hosted by Melissa Tomkiel, Strata's Co-Chief Executive Officer and General Counsel, and Will Heyburn, Strata's Co-Chief Executive Officer and Chief Financial Officer, and will include a question-and-answer session for call participants.
Strata Critical Medical: A Better Alternative To TransMedics In Organ Transplant Logistics
Strata Critical Medical is rated a buy, driven by expanding market share, operational efficiencies, and a comprehensive suite of transplant logistics and clinical services. SRTA's asset-light-to-moderate model, strategic acquisitions, and focus on NRP technology position it to benefit from industry consolidation and secular tailwinds. Gross margin improvement is a key near-term catalyst, with management incentivized to reach 25% margins by 2027; Q1 2026 gross margin reached 21%.
Strata Acquires Heart and Lung Transplant National Recovery Program, Expanding National Organ Recovery Platform
Network of experienced transplant surgeons in key markets will immediately become available to all Strata customers Adds significant scale to Transplant Clinical, Strata's fastest growing business line, with a similar, rapid growth trajectory $21.5 million acquisition completed at mid-single-digit multiple of Adjusted EBITDA, pre-synergy, consistent with Strata's capital deployment strategy NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), today announced that it has completed the acquisition of Heart and Lung Transplant National Recovery Program (“HLT-NRP”), a provider of transplant surgical recovery services in the United States. “HLT-NRP strengthens our organ recovery platform by significantly increasing our network of experienced transplant surgeons available to complete recoveries across the country adding clinical depth and geographic reach in key markets such as Florida and California,” said Will Heyburn, Co-CEO of Strata.
Strata Critical Medical, Inc. (SRTA) Surges 8.5%: Is This an Indication of Further Gains?
Strata Critical Medical, Inc. (SRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Strata Acquires Louisville Perfusion Services
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), today announced that it has completed the acquisition of Louisville Perfusion Services, Inc. (“LPS”), a regional provider of perfusion and blood management services to cardiac surgery programs in Kentucky. “The acquisition of Louisville Perfusion Services fits perfectly with our existing customer base in Kentucky and Ohio, giving us a new strategic stronghold in the Midwest and Southern United States,” said Lou Verdetto, CEO of Strata's Clinical Division.
AIAI Holdings Corporation Announces Appointment of Board of Directors
Directors bring a strong combination of technology, healthcare, national security, leadership experience, and financial and capital markets backgrounds AIAI Expected to Begin Trading on May 14, 2026 DALLAS, TX / ACCESS Newswire / May 12, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai2" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI to enhance portfolio performance, today announced the appointment of the Company's Board of Directors. John P. Rochon leads the 10-person Board as Chairman.
Strata Critical Medical Announces Expiration of Warrants
NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), announced that its warrants, both the Public Warrants (Nasdaq: SRTAW) and the Private Placement Warrants, expired in accordance with their original terms at 5:00 p.m. Eastern Time today May 7, 2026.
Strata Critical Medical, Inc. (SRTA) Q1 2026 Earnings Call Transcript
Strata Critical Medical, Inc. (SRTA) Q1 2026 Earnings Call Transcript
Strata Critical Medical Announces First Quarter 2026 Results
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced financial results for the first quarter ended March 31, 2026. Financial results in this release, including all comparisons to prior year periods, reflect continuing operations only. The results of the divested Passenger business have been reclassified as discontinued operations in all periods.
Strata Acquires Ohio Valley Perfusion Associates
NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced that it has completed the acquisition of Ohio Valley Perfusion Associates ("OVPA"), a regional provider of perfusion services to cardiac surgery programs in Ohio and Pennsylvania. “Expanding our presence in Eastern Ohio and Western Pennsylvania is an important step in strengthening Strata's regional clinical platform,” said Louis Verdetto, CEO of Strata's Clinical Services Division.
Strata Critical Medical Schedules First Quarter 2026 Earnings Conference Call
NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical. (Nasdaq: SRTA, “Strata” or the “Company”), will release financial results for the first quarter ended March 31, 2026 on Wednesday May 6, 2026 before the market opens.
Strata Critical Medical to Present at the 25th Annual Needham Virtual Healthcare Conference
NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026, at 1:30 pm ET. A webcast of the event will be available at the link here.
Strata Critical Medical: Significant Upside Potential Backed By Robust EBITDA Growth
Strata Critical Medical is rated 'Buy' with a 12–24 month horizon, targeting 30–35% upside as valuation remains attractive despite a recent rally. SRTA's transformation into a pure-play medical logistics provider, robust FY25 results, and margin expansion underpin confidence in forward guidance. Industry tailwinds, regulatory catalysts, and an aggressive acquisition strategy position SRTA for sustained revenue and EBITDA growth, with FY26 guidance implying an 11.6% EBITDA margin.
Strata Critical Medical, Inc. (SRTA) Q4 2025 Earnings Call Transcript
Strata Critical Medical, Inc. (SRTA) Q4 2025 Earnings Call Transcript
Strata Critical Medical Announces Fourth Quarter 2025 Results
Revenue increased 83.5% year-over-year to $66.8 million in Q4 2025 Logistics revenue and gross profit grew 35.3% and 39.5% year-over-year, respectively, in Q4 2025, which represents Strata's organic growth Full year 2025 net loss from continuing operations was $20.1 million Full year 2025 revenue and Adjusted EBITDA (1) of $197.1 million and $14.1 million, respectively, both beat the high end of our guidance range Raising full year 2026 revenue guidance to between $260 and $275 million and Adjusted EBITDA guidance to between $29 and $33 million (2) NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced financial results for the fourth quarter ended December 31, 2025. Financial results in this release, including all comparisons to prior year periods, reflect continuing operations only.
Strata Critical Medical Schedules Fourth Quarter 2025 Earnings Conference Call
NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical (Nasdaq: SRTA, “Strata” or the “Company”), will release financial results for the fourth quarter ended December 31, 2025 on Tuesday, March 3, 2026 before the market opens. The company will hold a conference call on the same day at 8:00 am Eastern Time to discuss the results. The call will be hosted by Will Heyburn, Strata's Co-Chief Executive Officer and Chief Financial Officer, and Melissa Tomkiel, Strata's Co-Chief Executive Officer and General Counsel, and will include a question-and-answer session for call participants.